---
title: "Reviva Pharmaceuticals | 8-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280997365.md"
datetime: "2026-03-30T10:13:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280997365.md)
  - [en](https://longbridge.com/en/news/280997365.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280997365.md)
---

# Reviva Pharmaceuticals | 8-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -5.48.

EBIT: As of FY2025, the actual value is USD -20.5 M.

The provided text indicates that Reviva Pharmaceuticals Holdings, Inc. issued a press release on March 30, 2026, disclosing financial information, operating metrics for its fiscal year ended December 31, 2025, and discussing its business outlook. However, the detailed financial figures, operational metrics, or specific business outlook statements are not present within the provided text itself.

### Related Stocks

- [RVPH.US](https://longbridge.com/en/quote/RVPH.US.md)

## Related News & Research

- [Reviva Pharmaceuticals Q1 net loss narrows on lower expenses](https://longbridge.com/en/news/286314912.md)
- [Dear Future SpaceX (SPCX) Stock Fans, Mark Your Calendars for June 12](https://longbridge.com/en/news/286809659.md)
- [Hub Group (HUBG) Shares Crater Again Amid Delayed Quarterly Report, Material Misstatements Now Include 2023 and 2024 Financial Reports - HBSS](https://longbridge.com/en/news/286453772.md)
- [XP Inc. Reports First Quarter 2026 Results | XP Stock News](https://longbridge.com/en/news/286814239.md)
- [Toppoint Holdings reports Q1 results](https://longbridge.com/en/news/286518575.md)